Other lipid agents × cardiovascular events

TrialThe New England journal of medicine2023

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.

Steven E Nissen et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 13,970 people · 2023

Randomised comparison

Reduced cardiovascular events

−13%−21% to −4%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.87, 95% CI 0.79–0.96

Randomised comparison

Reduced cardiovascular events

−15%−24% to −4%

Bigger than 3 in 10 for cardiovascular events

As reported

HR 0.85, 95% CI 0.76–0.96

Randomised comparison

Reduced cardiovascular events

−23%−34% to −9%

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.77, 95% CI 0.66–0.91

Randomised comparison

Reduced cardiovascular events

−19%−28% to −8%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.81, 95% CI 0.72–0.92

Four numbers in the abstract

the abstract, start to end

[11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92;

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.870.79–0.96
Cardiovascular events
HR 0.850.76–0.96
Cardiovascular events
HR 0.770.66–0.91
Cardiovascular events
HR 0.810.72–0.92
Other lipid agentsCardiovascular events
1 / 3

360 papers cite itlatest 60 shown

2023
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 36876740